Genetic Technologies (ASX:GTG) Forward Dividend Yield %: 0.00% (As of Jun. 27, 2026)


What is Genetic Technologies Forward Dividend Yield %?

Genetic Technologies ASX:GTG Forward Dividend Yield % is 0.00% as of Jun. 27, 2026.

As of today (2026-06-27), the Forward Annual Dividend Yield of Genetic Technologies is 0.00%.

As of today (2026-06-27), the Trailing Annual Dividend Yield of Genetic Technologies is 0.00%.

ASX:GTG's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.94
* Ranked among companies with meaningful Forward Dividend Yield % only.

Genetic Technologies's Dividends per Share for the three months ended in Jun. 2024 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Genetic Technologies  (ASX:GTG) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Genetic Technologies Forward Dividend Yield % Related Terms

ASX:GTG vs LDDD, NOTV, ATLN: Forward Dividend Yield % Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies Forward Dividend Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Forward Dividend Yield % falls into.


Genetic Technologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Genetic Technologies (ASX:GTG) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Forward Dividend Yield % too high?
Genetic Technologies' current Forward Dividend Yield % is 0.00%.
How does Genetic Technologies' Forward Dividend Yield % compare to LDDD and NOTV?
Genetic Technologies' Forward Dividend Yield % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Forward Dividend Yield % is 1.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.94, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Genetic Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Technologies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.